Bioactive homoisoflavonoids from the fibrous roots of Ophiopogon japonicus

IF 1.3 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2025-04-12 DOI:10.1016/j.phytol.2025.102962

Li-Ping Feng , Zhan-Guo Li , Qian Ding , Chun Luo , Xue-Ping Lu , Xiao-Hui Li

引用次数: 0

Abstract

Phytochemical exploration of the fibrous roots of Ophiopogon japonicus culminated in the identification of two novel homoisoflavonoids, designated as 5-O-methylophiopogonone C (1) and (3S)-7,2’-dihydroxy - 3’,4’-methylenedioxyhomoisoflavan (2). Leveraging an array of advanced spectroscopic methodologies, inclusive of nuclear magnetic resonance (NMR), infrared spectroscopy (IR), ultraviolet spectroscopy (UV), and high - resolution electrospray ionization mass spectrometry (HRESIMS), the structures of two isolated compounds were meticulously elucidated. Subsequently, their tyrosine kinase inhibitory activities were evaluated.

查看原文本刊更多论文

麦冬纤维根中具有生物活性的同型异黄酮

通过对日本麦冬（Ophiopogon japonicus）须根进行植物化学研究，最终发现了两种新型同异黄酮类化合物，分别为 5-O-甲基麦冬酮 C (1) 和 (3S)-7,2'-dihydroxy - 3',4'-methylenedioxyhomoisoflavan (2)。利用一系列先进的光谱方法，包括核磁共振（NMR）、红外光谱（IR）、紫外光谱（UV）和高分辨率电喷雾电离质谱（HRESIMS），这两种分离化合物的结构得到了细致的阐明。随后，对它们的酪氨酸激酶抑制活性进行了评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.